This HTML5 document contains 177 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n12http://dx.doi.org/10.1634/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q35863869
rdf:type
wikibase:Item
schema:description
2012年論文 2012年论文 articol științific vetenskaplig artikel artikulong pang-agham article scientific vitenskapelig artikkel ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2012年论文 wetenschappelijk artikel مقالة علمية نشرت بتاريخ 23-2-2012 επιστημονικό άρθρο 2012年論文 artigo científico научни чланак article científic artykuł naukowy scientific article published on 23 February 2012 2012年の論文 научна статия naučni članak articolo scientifico vědecký článek мақолаи илмӣ artículu científicu espublizáu en 2012 wissenschaftlicher Artikel vedecký článok artikel ilmiah bài báo khoa học 2012年论文 мақолаи илмӣ teaduslik artikkel научни чланак 2012年论文 tudományos cikk 2012年論文 artigo científico 2012年论文 videnskabelig artikel artikull shkencor מאמר מדעי სამეცნიერო სტატია article scientifique scientific article published on 23 February 2012 บทความทางวิทยาศาสตร์ 2012年論文 научная статья 2012年論文 artigo científico artículo científico publicado en 2012 2012년 논문 scientific article published on 23 February 2012 2012 nî lūn-bûn գիտական հոդված mokslinis straipsnis scienca artikolo bilimsel makale vitskapeleg artikkel tieteellinen artikkeli наукова стаття, опублікована в лютому 2012 2012年论文
p:P577
wds:Q35863869-28A6B298-485E-4DC3-8B2C-33E6F5A08FC9
wdt:P577
2012-02-23T00:00:00Z
p:P2860
wds:Q35863869-583CDDCA-3284-44CC-A4FB-D7620F8DFC05 wds:Q35863869-5D3B3BA2-A887-4149-BB6E-873188F016CA wds:Q35863869-681E2767-0FFB-4C8F-9681-FBDC4D9CB350 wds:Q35863869-7F4E2CCF-B11C-43FE-AB04-D6EF422E01BF wds:Q35863869-7F587E6E-C110-4C10-8E53-7E520ED6F8BE wds:Q35863869-80F207D6-EB4E-4483-A2AF-887160AD9ED6 wds:Q35863869-861BA499-B235-4D94-B9B9-7B3B12BD6122 wds:Q35863869-96546DB6-9373-4AD3-8F10-8A750376E25C wds:Q35863869-968C3311-63A6-4986-9B5D-88A168CFA84F wds:Q35863869-98EB35D1-10F5-4C7D-85D7-C7606FD98748 wds:Q35863869-A787F046-BB40-4184-A023-A4D8FC7B7A97 wds:Q35863869-AF111FFB-6297-46AB-BA85-5D824983288C wds:Q35863869-AFA6A729-4C97-40D3-AF1D-D39C49409B57 wds:Q35863869-B53EE7AD-8ED3-4D68-91ED-AB73A5D307D8 wds:Q35863869-D30F03CF-CA07-48F2-80B1-7A981C2F4988 wds:Q35863869-E3D30E4A-F63C-44C3-9C61-A1438AE43C0B wds:Q35863869-0851B88D-8A60-4B73-B3E7-193D628950B9 wds:Q35863869-10703865-AEE1-4339-9053-347A26B34ED7 wds:Q35863869-11234735-1D22-4BDB-8C82-1141BF9AC0EA wds:Q35863869-14DCB67F-6B36-4AC6-A833-3D825024DFB8 wds:Q35863869-1990DD9D-DBA4-44AB-BE82-D217562FAF01 wds:Q35863869-1B802D9C-1B5C-4ECB-BDC9-4DAF662EC74D wds:Q35863869-2B809A9D-C244-4632-B6A7-54C3C31CC91D wds:Q35863869-31A6F282-E7D3-40D1-B0D1-4982D0F9D1CC wds:Q35863869-32554BEE-41A0-4D4E-A5B7-791DE0811132 wds:Q35863869-47EF192E-8AF9-4992-B290-25F56A7F65F3
wdt:P2860
wd:Q50956129 wd:Q46181664 wd:Q73964368 wd:Q30913489 wd:Q33369393 wd:Q27851419 wd:Q33922925 wd:Q33372496 wd:Q71751952 wd:Q33370632 wd:Q34581085 wd:Q58218238 wd:Q30939008 wd:Q77555291 wd:Q33366028 wd:Q50588887 wd:Q44723047 wd:Q53232788 wd:Q57152185 wd:Q46538590 wd:Q46042915 wd:Q33342699 wd:Q29616236 wd:Q73311140 wd:Q40507956 wd:Q29619648
p:P2093
wds:Q35863869-A678464A-FD57-44C6-912D-764246DCB2F4 wds:Q35863869-94D7A24E-C307-4E1F-9493-309D4F4D8D86 wds:Q35863869-E8E58302-C2CB-47FD-A72E-60BAA69C00E2 wds:Q35863869-B2078CD2-857C-48E8-93F2-3BFCE2402FC2 wds:Q35863869-4D79B662-0A66-4F81-9FF9-97A6A4EC6504 wds:Q35863869-543005C2-7E6C-4291-BBCB-EAC76283934E wds:Q35863869-FABCC545-C658-4B93-9C4E-FA0110CD9D31 wds:Q35863869-80CE3A06-5C76-4CF2-A091-6407FC0E4DF7 wds:Q35863869-80772066-B949-4EC9-8FEE-8519B80CE6EF wds:Q35863869-00A72F07-AE17-48CB-9157-A1520ABED94A wds:Q35863869-3873847C-A670-4982-ADCC-0401C3E2B0CF
wdt:P2093
Bartomeu Massuti Fernando Rivera Eugenio Marcuello Javier Sastre Eduardo Díaz-Rubio Manuel Benavides Manuel Hidalgo Cristina Grávalos José L Manzano Manuel Valladares-Ayerbes Enrique Aranda
rdfs:label
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study
skos:prefLabel
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study
schema:name
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study
p:P1476
wds:Q35863869-B4DCB352-7A76-4CF6-930D-9D426E054EF8
wdt:P1476
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study
p:P304
wds:Q35863869-787950DB-7E82-4B26-A76D-DF8493DB7817
wdt:P304
339-345
p:P31
wds:Q35863869-92B38E58-E6E5-4680-A1D6-8135148630FB
wdt:P31
wd:Q13442814
p:P921
wds:Q35863869-377C970D-8977-4E94-BF55-C7F610EC7A13 wds:Q35863869-73930D3E-6DC4-4317-8274-B5FAA7A4C916 wds:Q35863869-EC37D693-04B1-4434-95A5-D4DE6DF9FB14 wds:Q35863869-FCB16098-7F49-4E3C-AF96-F5BF0855F680
wdt:P921
wd:Q25493920 wd:Q420207 wd:Q420296 wd:Q188874
p:P698
wds:Q35863869-CA8DD3C8-05E5-4A4F-B83D-BAC4DECBCF7B
wdtn:P698
n10:22363067
wdt:P698
22363067
p:P1433
wds:Q35863869-1F85D2E6-EC5E-407D-9764-09603AB549D3
wdt:P1433
wd:Q2122327
p:P433
wds:Q35863869-CFA30F7D-63E8-4EA2-8BDE-926025F1749C
p:P478
wds:Q35863869-EE2827D5-D662-450E-806E-C6ED8C1BFE26
wdt:P433
3
wdt:P478
17
p:P356
wds:Q35863869-5E23FACC-8679-48B7-A515-05D74569C849
wdtn:P356
n12:THEONCOLOGIST.2011-0406
wdt:P356
10.1634/THEONCOLOGIST.2011-0406
p:P5875
wds:Q35863869-7FDE5DE4-4F95-4469-BEB5-D467C88B6405
wdt:P5875
221859351
p:P932
wds:Q35863869-4BFCE5AF-5AA3-44C4-825D-373EBF7D5927
wdt:P932
3316919